Why it was recalled
Subpotent drug
Product description
Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01.
Lot numbers, UPCs & expiration codes
Lot #: 24C11, Exp 2/28/2026.
Where it was sold
Within U.S
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-0575-2025
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- Jul 29, 2025
- FDA report date
- Aug 20, 2025
- Quantity
- 29, 004 bottles
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- Pfizer
Original FDA data
Every field from FDA enforcement report D-0575-2025, exactly as published.
Show all FDA fields
- City
- Manhattan
- State
- NY
- Status
- Ongoing
- Country
- United States
- Event ID
- 97334
- Address
- 66 Hudson Blvd
- Code information
- Lot #: 24C11, Exp 2/28/2026.
- Postal code
- 10001
- Report date
- Aug 20, 2025
- Product type
- Drugs
- Recall number
- D-0575-2025
- Classification
- Class II
- Recalling firm
- Pfizer
- Product quantity
- 29, 004 bottles
- Reason for recall
- Subpotent drug
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01.
- Distribution pattern
- Within U.S
- Recall initiation date
- Jul 29, 2025
- Initial firm notification
- Letter
- Center classification date
- Aug 8, 2025